AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Latest Information Update: 17 Nov 2025
At a glance
- Drugs 707 3SBio (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 17 Nov 2025 New trial record